USA Techniques Stay Current on Entertainment News
  • Home
  • Cryptocurrency
  • Business
    • CEO
    • Entrepreneur
    • Founder
    • Journalist
    • Realtor
  • Health
    • Doctor
    • plastic Surgeon
    • Beauty Cosmetics
  • Sports
    • Athlete
    • Coach
    • Fitness Trainer
  • Entertainment
  • Science
  • USA
  • International
  • Politics
Thursday, Jan 15, 2026
USA Techniques Stay Current on Entertainment NewsUSA Techniques Stay Current on Entertainment News
Font ResizerAa
  • Home
  • Cryptocurrency
  • Business
  • Health
  • Sports
  • Entertainment
  • Science
Search
  • Home
  • Cryptocurrency
  • Business
    • CEO
    • Entrepreneur
    • Founder
    • Journalist
    • Realtor
  • Health
    • Doctor
    • plastic Surgeon
    • Beauty Cosmetics
  • Sports
    • Athlete
    • Coach
    • Fitness Trainer
  • Entertainment
  • Science
Follow US
Home » Blog » Mphasis Q4 profit rises 13.6% to ₹446 cr
Business

Mphasis Q4 profit rises 13.6% to ₹446 cr

Michael Hayes
Michael Hayes
Share
SHARE

Nitin Rakesh, Executive Director and Managing Director of Mphasis

Nitin Rakesh, Executive Director and Managing Director of Mphasis | Photo credit: Somashekara Grn

The company of Ti Mhasis said Friday that its net gain grew by 13.6 percent to ₹ 446.5 million rupees in January-March of the quarter of fiscal year 2015, promoted by higher margins and higher revenues of the BFSI segment.

The company had reported a fair gain of ₹ 393.21 million rupees in the same period a year ago, Mhahasis said in a regulatory presentation.

“We are pleased with a quarter of Broad-Based Performance, Reporting the Highest Quarter-On-Quarter (Qoq) Growth in 12 Quarters, Highest TCV (Total Contract Value) Wins In 7 Quarters, Highest Ever Quarterly and Full Yart Ths and in Ths and in Ths and in Ths and in Ths and in Ths and in Ths and in Ths and in Ths and in Ths and in Ths and in THS and 86 in THS and 86 for THS and 86 per year.

The consolidated revenues of the mhasis operations grew by 8.7 percent to ₹ 3,710 million rupees that define the quarter reported ₹ 3,412 million rupees in March 2024 quarter.

The company’s operational margins were 15.3 percent of the fourth quarter, as well as in the year ended in March 2025. The figure was slightly higher than the two comparative figures or the 14.9 percent and 15.1 record in the previous prosecutor.

Mhasis has an objective or operational margin to be within the band or 14.75-15.75 percent and the general growth to be above the average industry due to the profits of the agreements.

The total value of the contract of the new victories in the informed quarter doubled to $ 390 million, around ₹ 3,330 million rupees, of $ 177 million a year ago.

The banking segment, financial services and insurance of Mphasis, the largest taxpayer to its general income, grew by approximately 11 percent to $ 215 million in the last period of January-March of $ 193 million in the quarter of the previous year.

For the year ended in March 2025, the company’s net profit grew by 9.5 percent to ₹ 1,702.1 million rupees of ₹ 1,554.8 million rupees in the fiscal year24.

The annual revenues of the Mhasis operations grew by 7.16 percent to ₹ 14,230 million rupees in fiscal year 2015 since ₹ 13,279 million rupees in fiscal year 200

Posted on April 25, 2025

Share This Article
Facebook Copy Link Print

Recent Posts

  • Cassidy’s Warning on Changes to U.S. Childhood Vaccine Schedule
  • A Sweeter Shade of Natural: Ice Cream Makers Commit to Ditch Artificial Dyes by 2028
  • A Diplomatic Gesture: Trump’s 75th Birthday Call to PM Modi
  • Generative AI in Classrooms: Transforming K-12 Science and Math Education
  • Tech Meets Nature: Smart Gardening Tools Changing the Way Americans Grow

Recent Comments

No comments to show.

You Might Also Like

Business

Former ISRO chief K Kasturirangan passes away in Bengaluru

1 Min Read
Business

With RBI easing rules for computation of LCR, banks may have more resources to lend

4 Min Read
Business

AIFs pump ₹74,000 crore into real estate, highest among all sectors: Anarock

4 Min Read
Business

Lupin gets USFDA nod for generic kidney disease treatment drug

2 Min Read
USA Techniques Stay Current on Entertainment News
  • USA
  • Science
  • International
  • Entertainment
  • Cryptocurrency
  • Business
  • CEO
  • Realtor
  • Founder
  • Journalist
  • Entrepreneur
  • Health
  • Doctor
  • Beauty Cosmetics
  • plastic Surgeon
  • Sports
  • Athlete
  • Coach
  • Fitness Trainer

© 2017-2026 usatechniques. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?